Xaga Surgical, a Helsingborg-based medtech startup, has raised €697K (SEK 8 million) in a funding round led by Almi Invest, with participation from SmiLe Inject Capital and private investors. The company develops advanced medical needles designed to reduce bacterial transfer during biopsies by 96%, significantly lowering the risk of infections and enhancing cancer diagnostics. Founded in 2016 by urologist Andreas Forsvall, Xaga Surgical was inspired by real patient cases where sepsis developed after prostate biopsies. The fresh capital will fuel the company’s commercialization efforts, secure FDA approval, and support its entry into the U.S. market.
Xaga Surgical develops biopsy needles designed to reduce bacterial transfer and lower the risk of infections. Founded in 2016 by urologist Andreas Forsvall, the company was established in response to concerns about infection risks associated with conventional biopsy procedures. Xaga Surgical’s patented technology aims to improve patient safety and diagnostic accuracy. Based in Helsingborg, the company is working toward regulatory approvals and broader market adoption.
“Our investment in Xaga Surgical is an example of how we support innovations that make a real difference. Through their groundbreaking technology, we can help contribute to safer healthcare and strengthen Swedish competitiveness in a global market,” says Faten Mustafa, Investment Manager at Almi Invest.
The investment round is being participated by Smile Capital and private investors, who together with Almi Invest are contributing capital and strategic expertise to enable Xaga Surgical’s vision of a globally better and safer healthcare system.
“Our investment in Xaga Surgical is part of our commitment to supporting life science companies in commercializing their innovations to contribute to global health,” said Thomas Unt, CEO of SmiLe Inject Capital. “Xaga Surgical has an exceptionally skilled team and a unique innovation that has garnered significant attention, promising to enhance the safety of cancer diagnostics.”
SmiLe Inject Capital is Sweden’s only angel investment company focusing on promising early-stage life science companies. Through SmiLe Inject Capital, private investors gain access to SmiLe’s extensive life science expertise, international networks, and unique insights into early-stage life science companies. The funding is supported by experienced business angels along with the state-owned venture capital company Saminvest.
“The global medical needle market faces significant challenges. Over 50 million people are at risk of health problems linked to needlestick infections annually, with estimated costs of USD 80 billion. Our technology is designed to address this need and create safer and more effective healthcare solutions,” says Andreas Forsvall, Founder and CEO of Xaga Surgical.
Xaga Surgical is part of SmiLe’s incubator program.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/xaga-surgical-raises-e697k/
